SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

UPDATE: Wedbush Upgrades Arbutus Biopharma To Outperform, Raises Target To $4 'following positive 12-Week 60 mg single-dose data for AB-729 in chronic HBV patients'

Benzinga · 05/19/2020 16:14